Evidence map›Paper›PMID 35345867›Full record

ArticleClinical and translational radiation oncology2022

Availability of technology for managing cancer patients in the Southeast European (SEE) region.

Manjit Dosanjh, Mimoza Ristova, Vesna Gershan, Petya Georgieva, Marijana Balin Kovacevic, Ledio Bregu, Irma Coralic, Tamara Djurovic, Deyana Dosieva, Yiota Foka and 19 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Manjit DosanjhCERN, Geneva, Switzerland.
Mimoza RistovaCERN, Geneva, Switzerland.
Vesna GershanFaculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University in Skopje, North Macedonia.
Petya GeorgievaCERN, Geneva, Switzerland.
Marijana Balin KovacevicSerbian Radiation and Nuclear Safety and Security Directorate, Serbia.
Ledio BreguHygeia Hospital, Tirana, Albania.
Irma CoralicState Regulatory Agency for Radiation and Nuclear Safety, Bosnia and Herzegovina.
Tamara DjurovicMinistry of Ecology, Spatial Planning and Urbanism, Montenegro.
Deyana DosievaBulgarian Regulatory Agency, Bulgaria.
Yiota FokaCERN, Geneva, Switzerland.
Ana FröbeUniversity Hospital Clinic, Sestre Milisrdnice, Zagreb, Croatia.
Konstantinos HatziioannouPapageorgiou General Hospital, Thessaloniki, Greece.
Costas J HourdakisGreek Atomic Energy Commission, Greece.
Yllka KabashiInstitute of Oncology, University Clinical Center of Kosovo.
Dimitar KalevSHATOD "Dr. Marko Markov", Varna Ltd, Varna, Bulgaria.
Ilir KurtishiInstitute of Oncology, University Clinical Center of Kosovo.
Leandar LitovCERN, Geneva, Switzerland.
Beqir MezelxhiuKosovo Agency for Radiation Protection and Nuclear Safety, Kosovo.
Svetlana Nestoroska MadjunarovaFaculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University in Skopje, North Macedonia.
Gordana NikolovaRadiation Safety Directorate, Skopje, North Macedonia.
Damijan SkrkSlovenian Radiation Protection Administration and Faculty of Mathematics and Physics, Slovenia.
Velda SmajlbegovicClinical Centre of Sarajevo University, Bosnia & Herzegovina.
Snezana SmichkoskaUniversity Clinic of Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, North Macedonia.
Igor StojkovskiUniversity Clinic of Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, North Macedonia.
Primož StrojanDept. of Radiotherapy, Institute of Oncology Ljubljana, Slovenia.
Zdravka TecicMinistry of the Interior, Civil Protection Directorate, Sector for Radiological and Nuclear Safety, Croatia.
Dušanka TešanovićOncology Institute of Vojvodina, Sremska Kamenica, Serbia.
Vladimir TodorovicSEEIIST Association, Geneva, Switzerland.
Zdravka ValerianovaBulgarian National Cancer Registry, Bulgaria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Southeast European (SEE) region of 10 countries and about 43 million people differs from Western Europe in that most SEE countries lack active cancer registries and have fewer diagnostic imaging devices and radiotherapy (RT) units. The main objective of this research is to initiate a common platform for gathering SEE regional cancer data from the ground up to help these countries develop common cancer management strategies. Methods: To obtain detailed on-the-ground information, we developed separate questionnaires for two SEE groups: a) ONCO - oncologists regarding cancer treatment modalities and the availability of diagnostic imaging and radiotherapy equipment; and b) REG - national radiation protection and safety regulatory bodies regarding diagnostic imaging and radiotherapy equipment in SEE facilities. Results: Based on responses from 13/17 ONCO participants (at least one from each country) and from 9/10 REG participants (all countries but Albania), cancer incidence rates are higher in those SEE countries that have greater access to diagnostic imaging equipment while cancer mortality-to-incidence (MIR) ratios are higher in countries that lack radiotherapy equipment. Conclusion: By combining unique SEE region information with data available from major global databases, we demonstrated that the availability of diagnostic imaging and radiotherapy equipment in the SEE countries is related to their economic development. While immediate diagnostic imaging and radiation therapy capacity building is necessary, it is also essential to develop both national and SEE-regional cancer registries in order to understand the heterogeneity of each country's needs and to establish regional collaborative strategies for combating cancer.

Indexed as

Cancer patientsCancer registriesDiagnostic equipmentRadiation therapy equipmentSEEIISTSEE region

Identifiers

PMID35345867
PMCPMC8956881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.